DrugPrimer Archive - Cancer Therapy Advisor

Archives: DrugPrimer

Jemperli for Mismatch Repair-Deficient Recurrent or Advanced Endometrial Cancer

The pooled safety population comprised 444 patients with advanced or recurrent solid tumors who were exposed to Jemperli. Of those patients, 268 had endometrial cancer and 176 had a different solid tumor. Thirty-eight percent of patients were exposed to Jemperli for at least 6 months; 12% were exposed for greater than 1 year.  Safety data were…

Blenrep for the Treatment of Relapsed/Refractory Multiple Myeloma

Efficacy of Blenrep Safety Findings of the DREAMM-2 Study Blenrep Dose Modifications for Adverse Reactions Blenrep REMS Posted by Haymarket’s Clinical Content Hub. The editorial staff of Cancer Therapy Advisor had no role in this content’s preparation. Reviewed September 2020

Next drugprimer in Drug Primer